Patents by Inventor William C. Sessa
William C. Sessa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210403549Abstract: In one aspect, the invention comprises a fusion construct comprising ALKI extracellular domain and a stability enhancing domain. In another aspect, the invention comprises an antibody that interferes with or blocks the ALKI extracellular domain binding to LDL, but does not interfere with or block the ALKI extracellular domain binding to BMP9/10. In yet another aspect, the invention comprises methods of reducing rates of LDL uptake in the endothelial cells of a patient in need thereof by administering the fusion construct or monoclonal antibodies described herein to the patient.Type: ApplicationFiled: May 17, 2018Publication date: December 30, 2021Inventors: William C. SESSA, Jan KRAEHLING
-
Patent number: 10550151Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.Type: GrantFiled: March 2, 2018Date of Patent: February 4, 2020Assignee: Yale UniversityInventors: William C. Sessa, Frank J. Giordano
-
Patent number: 10537607Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.Type: GrantFiled: November 21, 2014Date of Patent: January 21, 2020Assignee: E&B Technologies LLCInventors: David Eveleth, William C. Sessa
-
Publication number: 20190225660Abstract: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and edema. The methods comprise administering to a subject an agent which comprises a caveolin scaffolding domain. The present invention further encompasses methods of treating and preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.Type: ApplicationFiled: October 2, 2018Publication date: July 25, 2019Inventor: William C. SESSA
-
Publication number: 20180250325Abstract: The present invention provides miR-19 modulators and uses thereof, such as for promoting angiogenesis and/or wound healing with miR-19 inhibitors alone or in combination with other agents. The present invention also provides methods of treating or preventing arterial and cardiac conditions with a miR-19 inhibitor. Also provided are oligonucleotides with chemical motifs that are miR-19 inhibitors, and methods of using the oligonucleotides for inhibiting the function or activity of miR-19 in a subject in need thereof.Type: ApplicationFiled: September 22, 2016Publication date: September 6, 2018Inventors: William C. SESSA, Christina Marie DALBY, Corrie Lynn GALLANT-BEHM
-
Publication number: 20180201649Abstract: The invention includes an isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell. The invention also includes a transport construct in which a transport peptide is linked to a cargo moiety to be delivered into a cell. The invention further includes a method of delivering a transport construct into and/or to a cell.Type: ApplicationFiled: March 2, 2018Publication date: July 19, 2018Inventors: William C. SESSA, Frank J. GIORDANO
-
Patent number: 9908915Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell, is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.Type: GrantFiled: November 20, 2014Date of Patent: March 6, 2018Assignee: Yale UniversityInventors: William C. Sessa, Frank J. Giordano
-
Publication number: 20170128520Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.Type: ApplicationFiled: November 21, 2014Publication date: May 11, 2017Applicant: E&B TECHNOLOGIES LLCInventors: David EVELETH, William C. SESSA
-
Publication number: 20160289269Abstract: The invention includes an isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell. The invention also includes a transport construct in which a transport peptide is linked to a cargo moiety to be delivered into a cell. The invention further includes a method of delivering a transport construct into and/or to a cell.Type: ApplicationFiled: November 20, 2014Publication date: October 6, 2016Applicant: Yale UniversityInventors: William C. SESSA, Frank J. GIORDANO
-
Publication number: 20150141340Abstract: The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema.Type: ApplicationFiled: May 30, 2013Publication date: May 21, 2015Inventor: William C. Sessa
-
Patent number: 8349798Abstract: The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions.Type: GrantFiled: October 30, 2007Date of Patent: January 8, 2013Assignee: Yale UniversityInventor: William C. Sessa
-
Publication number: 20120149651Abstract: The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions.Type: ApplicationFiled: October 30, 2007Publication date: June 14, 2012Applicant: Yale UniversityInventor: William C. Sessa
-
Patent number: 8084228Abstract: Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding the Nogo-B receptor and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B receptor-related diseases, disorders and conditions.Type: GrantFiled: January 12, 2007Date of Patent: December 27, 2011Assignee: Yale UniversityInventors: William C. Sessa, Quing Miao
-
Publication number: 20110173711Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Inventor: William C. Sessa
-
Patent number: 7888089Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.Type: GrantFiled: December 9, 2008Date of Patent: February 15, 2011Assignee: Yale UniversityInventor: William C. Sessa
-
Patent number: 7767641Abstract: The present invention relates to previously unknown biological roles of Nogo-B. We have discovered that Nogo-B is a component of endothelial cells. We have also discovered that Nogo-B is highly expressed in intact blood vessels. The amino terminus of Nogo-B promotes the adhesion, spreading and migration of endothelial cells and plays a role in vascular remodeling. Thus, Nogo-B is a novel regulator of vascular homeostasis and remodeling. The present invention provides compositions comprising Nogo-B and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding Nogo-B and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for Nogo-B and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B-related diseases, disorders and conditions.Type: GrantFiled: April 23, 2004Date of Patent: August 3, 2010Assignee: Yale UniversityInventors: William C. Sessa, Lisette Acevedo
-
Publication number: 20090305971Abstract: Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding the Nogo-B receptor and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B receptor-related diseases, disorders and conditions.Type: ApplicationFiled: January 12, 2007Publication date: December 10, 2009Applicant: YALE UNIVERSITYInventors: William C. Sessa, Quing Miao
-
Publication number: 20090246183Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.Type: ApplicationFiled: December 9, 2008Publication date: October 1, 2009Applicant: Yale UniversityInventor: William C. Sessa
-
Patent number: 7494976Abstract: The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions.Type: GrantFiled: February 4, 2003Date of Patent: February 24, 2009Assignee: Yale UniversityInventor: William C. Sessa
-
Patent number: 6900038Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.Type: GrantFiled: September 20, 2001Date of Patent: May 31, 2005Assignee: Yale UniversityInventor: William C. Sessa